期刊
HAEMATOLOGICA
卷 100, 期 11, 页码 E450-E453出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2015.132837
关键词
JAK mutations; CTCL; ruxolitinib; JAK/STAT; targeted therapy; molecular diagnostics